Cargando…

PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma

Targeted combined immunotherapy has significantly improved the prognosis of patients with advanced hepatocellular carcinoma and has now become the primary treatment for advanced hepatocellular carcinoma. However, some patients still have poor efficacy or are resistant to treatment. The further explo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yinkui, Qiu, Xiusheng, Wu, Donghao, Lu, Xu, Li, Guanghui, Tang, Yongsheng, Jia, Changchang, Xiong, Zhiyong, Wang, Tiantian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498926/
https://www.ncbi.nlm.nih.gov/pubmed/36140703
http://dx.doi.org/10.3390/genes13091535
_version_ 1784794881665794048
author Chen, Yinkui
Qiu, Xiusheng
Wu, Donghao
Lu, Xu
Li, Guanghui
Tang, Yongsheng
Jia, Changchang
Xiong, Zhiyong
Wang, Tiantian
author_facet Chen, Yinkui
Qiu, Xiusheng
Wu, Donghao
Lu, Xu
Li, Guanghui
Tang, Yongsheng
Jia, Changchang
Xiong, Zhiyong
Wang, Tiantian
author_sort Chen, Yinkui
collection PubMed
description Targeted combined immunotherapy has significantly improved the prognosis of patients with advanced hepatocellular carcinoma and has now become the primary treatment for advanced hepatocellular carcinoma. However, some patients still have poor efficacy or are resistant to treatment. The further exploration of molecular markers related to efficacy or finding molecular targets to increase efficacy is an urgent problem that needs to be resolved. In this research, we found that PROZ was a gene related to KDR expression that had significantly low expression in cancer tissue by analyzing the differential genes of cancer tissue and adjacent tissue and the intersection of KDR-related genes in hepatocellular carcinoma. The correlation analysis of clinical data showed that the low expression of PROZ was significantly correlated with the poor prognosis of hepatocellular carcinoma, and further studies found that PROZ was closely related to the expression of p-ERK and VEGFR2 in hepatocellular carcinoma. In addition, intracellular detection also showed that the expression of p-ERK increased and VEGFR2 expression decreased after PROZ interference, and PROZ downregulation with increased p-ERK and decreased VEGFR2 was also detected in sorafenib-resistant strains. At the same time, our analysis found that PROZ was negatively correlated with genes related to immunotherapy efficacy such as CD8A, CD274 and GZMA, and was also negatively correlated with T-cell infiltration in tumor tissue. Conclusion: PROZ is a gene related to the prognosis of hepatocellular carcinoma and it is closely related to the efficacy of sorafenib and immunotherapy. It may serve as a potential molecular target to improve the efficacy of targeted combined immunotherapy.
format Online
Article
Text
id pubmed-9498926
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94989262022-09-23 PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma Chen, Yinkui Qiu, Xiusheng Wu, Donghao Lu, Xu Li, Guanghui Tang, Yongsheng Jia, Changchang Xiong, Zhiyong Wang, Tiantian Genes (Basel) Article Targeted combined immunotherapy has significantly improved the prognosis of patients with advanced hepatocellular carcinoma and has now become the primary treatment for advanced hepatocellular carcinoma. However, some patients still have poor efficacy or are resistant to treatment. The further exploration of molecular markers related to efficacy or finding molecular targets to increase efficacy is an urgent problem that needs to be resolved. In this research, we found that PROZ was a gene related to KDR expression that had significantly low expression in cancer tissue by analyzing the differential genes of cancer tissue and adjacent tissue and the intersection of KDR-related genes in hepatocellular carcinoma. The correlation analysis of clinical data showed that the low expression of PROZ was significantly correlated with the poor prognosis of hepatocellular carcinoma, and further studies found that PROZ was closely related to the expression of p-ERK and VEGFR2 in hepatocellular carcinoma. In addition, intracellular detection also showed that the expression of p-ERK increased and VEGFR2 expression decreased after PROZ interference, and PROZ downregulation with increased p-ERK and decreased VEGFR2 was also detected in sorafenib-resistant strains. At the same time, our analysis found that PROZ was negatively correlated with genes related to immunotherapy efficacy such as CD8A, CD274 and GZMA, and was also negatively correlated with T-cell infiltration in tumor tissue. Conclusion: PROZ is a gene related to the prognosis of hepatocellular carcinoma and it is closely related to the efficacy of sorafenib and immunotherapy. It may serve as a potential molecular target to improve the efficacy of targeted combined immunotherapy. MDPI 2022-08-26 /pmc/articles/PMC9498926/ /pubmed/36140703 http://dx.doi.org/10.3390/genes13091535 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Yinkui
Qiu, Xiusheng
Wu, Donghao
Lu, Xu
Li, Guanghui
Tang, Yongsheng
Jia, Changchang
Xiong, Zhiyong
Wang, Tiantian
PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
title PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
title_full PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
title_fullStr PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
title_full_unstemmed PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
title_short PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma
title_sort proz associated with sorafenib sensitivity may serve as a potential target to enhance the efficacy of combined immunotherapy for hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498926/
https://www.ncbi.nlm.nih.gov/pubmed/36140703
http://dx.doi.org/10.3390/genes13091535
work_keys_str_mv AT chenyinkui prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT qiuxiusheng prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT wudonghao prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT luxu prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT liguanghui prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT tangyongsheng prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT jiachangchang prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT xiongzhiyong prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma
AT wangtiantian prozassociatedwithsorafenibsensitivitymayserveasapotentialtargettoenhancetheefficacyofcombinedimmunotherapyforhepatocellularcarcinoma